Human Epididymis Protein 4 (HE4) in Patients with Small-Cell Lung Cancer.
BACKGROUND
The aim of the present study was to compare the diagnostic utility of HE4 with NSE, ProGRP, CYFRA 21-1, CEA, and CA 125 and evaluate their prognostic value in patients with small-cell lung cancer (SCLC).


METHODS
HE4, ProGRP, NSE, CYFRA 21-1, CEA, and CA 125 assays were performed in 63 patients with smallcell lung cancer (limited disease (LD) - 41, extensive disease (ED) - 22) and in 66 individuals of the reference group.


RESULTS
Area under the ROC curves for HE4, ProGRP, NSE, CA 125, CYFRA 21-1, and CEA were 0.884, 0.923, 0.826, 0.796, 0.739, and 0.704, respectively. The tumor marker serum concentrations were associated with tumor stage (HE4, ProGRP, NSE, CYFRA 21-1, CEA), and disease progression occurred within one year (HE4, ProGRP, NSE, CYFRA 21-1). The tumor advancement, performance status, gender and tumor markers, except CEA and CA 125, were significantly associated with survival. Independent, unfavourable prognostic factors included extensive disease (HR 4.14, p < 0.0001) and NSE concentration above 35 g/l (HR 2.62, p = 0.0009).


CONCLUSIONS
Diagnostic utility of HE4 was similar to that of NSE and ProGRP. Complementary to NSE, determination of HE4 seems to be helpful in evaluation of SCLC patients' prognosis.
Ewa
E
Wojcik
Jadwiga
J
Tarapacz
Urszula
U
Rychlik
Zofia
Z
Stasik
Beata
B
Sas-Korczynska
Piotr
P
Skotnicki
Jan K
JK
Kulpa
D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood; D019540:Area Under Curve; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D005260:Female; D006801:Humans; D053539:Keratin-19 / Q000097:blood; D008175:Lung Neoplasms / Q000097:blood* / Q000175:diagnosis; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000097:blood; D010751:Phosphopyruvate Hydratase / Q000097:blood; D011379:Prognosis; D011498:Protein Precursors / Q000097:blood; D011506:Proteins / Q000032:analysis*; D055752:Small Cell Lung Carcinoma / Q000097:blood* / Q000175:diagnosis; D000081102:WAP Four-Disulfide Core Domain Protein 2
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D002272:Carcinoembryonic Antigen; D053539:Keratin-19; D010455:Peptides; D011498:Protein Precursors; D011506:Proteins; D000081102:WAP Four-Disulfide Core Domain Protein 2; C569698:WFDC2 protein, human; C102012:antigen CYFRA21.1; C047897:gastrin-releasing peptide precursor; D010751:Phosphopyruvate Hydratase